Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert video report on Prostate Cancer from 2021 Genitourinary Cancers Symposium

Reporting from the 2021 Genitourinary Cancers Symposium, Karen Knudsen comments on results from CRPC studies looking at molecular determinants associated with long term response to apalutamide in the SPARTAN study, and the final results from the ACIS study testing the addition of apalutamide to abiraterone and prednisone in metastatic disease.
She also gives an overview of the final results from the TITAN study testing apalutamide in metastatic castration-sensitive setting receiving ADT.


  • Abstract 8: Molecular determinants associated with long-term response to apalutamide in nonmetastatic castration-resistant prostate cancer, Felix Feng
  • Abstract 9: Final results from ACIS, a randomized, placebo-controlled double-blind phase 3 study of apalutamide and abiraterone acetate plus prednisone versus AAP in patients with chemo-naive metastatic castration-resistant prostate cancer, Dana Rathkopf
  • Abstract 11: Final analysis results from TITAN: A phase III study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy, Kim Chi

This video was supported with an educational grant from Janssen Oncology

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.